Bloom's syndrome (BS) is a rare human autosomal recessive disorder characterized by an increased risk to develop cancer of all types. BS cells are characterized by a generalized genetic instability including a high level of sister chromatid exchanges. BS arises through mutations in both alleles of the BLM gene which encodes a 3' ± 5' DNA helicase identi®ed as a member of the RecQ family. We developed polyclonal antibodies speci®c for the NH 2 -and COOH-terminal region of BLM. Using these antibodies, we analysed BLM expression during the cell cycle and showed that the BLM protein accumulates to high levels in S phase, persists in G2/ M and sharply declines in G1, strongly suggestive of degradation during mitosis. The BLM protein is subject to post-translational modi®cations in mitosis, as revealed by slow migrating forms of BLM found in both demecolcine-treated cells and in mitotic cells isolated from non-treated asynchronous populations. Phosphatase treatment indicated that phosphorylation events were solely responsible for the appearance of the retarded moieties, a possible signal for subsequent degradation. Together, these results are consistent with a role of BLM in a replicative (S phase) and/or post-replicative (G2 phase) process.
Introduction
Bloom's syndrome (BS) is a rare human autosomal recessive disorder associated with growth retardation, immunode®ciency and predisposition to development of all kinds of cancer aecting the general population (reviewed in German, 1993) . Besides these clinical manifestations, cells from BS patients exhibit a mutator phenotype associated with a number of cytogenetic abnormalities including increases of chromosome breaks, symmetric quadriradial chromatid interchanges between homologous chromosomes and sister chromatid exchanges (SCE) (reviewed in German, 1993 ). Bloom's syndrome arises through mutations in both alleles of the BLM gene, which is located on chromosome 15 at 15q26.1. The BLM protein has been identi®ed as a member in the DExH boxcontaining RecQ helicase subfamily (Ellis et al., 1995) . Its primary sequence presents similarities with all known members in the RecQ subfamily, including Escherichia coli RecQ (Umezu et al., 1990) , Saccharomyces cerevisiae Sgs1p (Ganglo et al., 1994; Watt et al., 1995) , Schizosaccharomyces pombe Rqh1 (Stewart et al., 1997) , Drosophila melanogaster DmBLM (Kusano et al., 1999) , human RecQL (Puranam and Blackshear, 1994; Seki et al., 1994) , human Wrn, the product of the Werner's syndrome gene (Yu et al., 1996) and the recently identi®ed human RecQ4 and RecQ5 proteins (Kitao et al., 1998) . Chester et al. (1998) developed a mouse model for the human Bloom's syndrome, and showed that mouse embryos homozygous for a targeted mutation in the murine Bloom's syndrome gene die by embryonic day 13.5, but little is known about function(s) of BLM. It has been shown that recombinant BLM displays an ATP-and Mg2+ dependent 3' ± 5'-DNA helicase activity (Karow et al., 1997) which is required to correct the genomic instability inherent to BS cells (Bahr et al., 1998; Ne et al., 1999) . In the RecQ subfamily, phylogenetic analyses have revealed that the BLM protein is most closely related to Schizosaccharomyces pombe Rqh1 and to Saccharomyces cerevisiae Sgs1p (Murray et al., 1997; Kitao et al., 1998) . Rqh1, which prevents excessive recombination (Stewart et al., 1997) and takes part in a S phase mechanism allowing the bypass of unrepaired DNA damage during DNA synthesis (Murray et al., 1997) , is crucial for recovery from S phase arrest in ®ssion yeast. In budding yeast, Sgs1p is directly involved in the S phase checkpoint response (Frei and Gasser, 2000) . Based on their phylogenetic proximity, we hypothesized that similar to Rqh1 and Sgs1p, BLM could also function at speci®c phases(s) of the cell cycle. We here present an analysis of BLM expression during the cell cycle. The endogenous BLM protein is low in G1, accumulates in S and G2/M phases and is hyperphosphorylated in mitosis, consistent with a possible implication of BLM in a replicative and/or post replicative process.
endogenous BLM helicase was carried out by immunoblot analysis using the 1340 and 1343 antibodies which are directed towards the NH2-and COOHterminal region of the BLM protein, respectively. Figure 1 shows that both 1340 and 1343 detected a band migrating at approximately 175 kDa in cell extracts prepared from normal EBV-transformed lymphoblastoid B cells (Priess) and from HeLa cells. This band was not detected in extracts prepared from BS EBV-transformed lymphoblastoid B cells (GM03403D) or from BS SV40-transformed ®broblasts (GM08505B). These two cell lines are homozygous for the blm Ash allele which contains a frameshift mutation commonly found in patients from Ashkenazi Jewish ancestry, leading to a truncated protein of 739 amino acid in length (Ellis et al., 1995) . This truncated BLM protein was not detectable in BS extracts (data not shown) probably because it is not stable. Comparable amounts of proteins were present in the dierent lanes as veri®ed by staining the membranes with Coomassie blue (data not shown).
The BLM protein accumulates in S phase of the cell cycle
In order to analyse the BLM protein expression under physiological conditions during the cell cycle we used ow cytometry to sort unsynchronized HeLa cells in G1, S and G2/M phases, on the basis of their DNA content. In parallel, because BLM defect is known to result in abnormalities associated with replication (Hand and German, 1975; Gianneli et al., 1977; Lonn et al., 1990) , we treated HeLa cells with two DNA replication inhibitors which both block chain elongation (Levenson and Hamlin, 1993) : hydroxyurea which inhibits ribonucleotide reductase (Skoog and NordenskjoÈ ld, 1971) and aphidicolin which interacts with DNA polymerases (Wang, 1991) . G1, S and G2/M sorted HeLa cells were compared to untreated, aphidicolin or hydroxyurea treated HeLa cells for expression of BLM as detected by Western blot analysis using the 1340 antibody. As shown in Figure  2a , the BLM protein, hardly detectable in G1, accumulates in the S and G2/M phases of the cell cycle. The same results were obtained using the EBVtransformed lymphoblastoid Priess cells (data not shown). Furthermore, the amount of BLM protein is higher in cells treated with chain elongation inhibitors than in cycling cells, and corresponds to the amount of BLM protein detected in S phase cells (Figure 2a) . Relative DNA contents of all analysed cells were measured by¯ow cytometry and are displayed in Figure 2b . As expected for treatments with elongation inhibitors, we observed a decrease in the number of cells in G2/M in the drug-treated population as compared to the drug-free control (Levenson and Hamlin, 1993) .
Taken together, our results indicate that during the cell cycle, the BLM protein accumulates during S and G2/M phases, prior to decrease strongly in G1.
The BLM protein is subject to mitosis-associated post-translational modifications As shown in Figure 2a , the cellular level of BLM protein within the G2/M phase of the cell cycle is similar to that observed within the S phase, but it is strongly lower during the G1 phase, suggesting that BLM could be degraded during mitosis. These results prompted us to analyse in detail BLM expression during mitosis. Thus, we treated HeLa cells with the microtubules-disrupting agent demecolcine (Rodman et al, 1980) and with the microtubules-stabilizing agent taxol (Jordan et al., 1993) . Determination of DNA content by¯ow cytometry con®rmed that most cells were arrested at G2/M phase (data not shown). 5610 5 demecolcine or taxol-treated cells were used for Western blot analysis. As shown in Figure 3a , an important and complete size shift of the BLM protein was observed in both demecolcine and taxol-arrested cells. Identical results were obtained using two other cell lines, the epithelial cells MCF7 and hematopoietic cells K562 (data not shown).
To determine whether the appearance of the slow migrating band correlated with a progressive accumulation of cells in metaphase, we followed the time course of demecolcine eect on the BLM migration shift. As shown in Figure 3b , a progressive appearance of the slower migrating band was observed starting when approximately 70% of the cells were blocked in Figure 1 Detection of the BLM helicase by using the 1340 and 1343 antibodies. 5610 5 non BS (HeLa and Priess) and BS (GM08505B and GM03403D) cells were lysed in hot SDS and separated on 5.5% polyacrylamide gel and transferred onto PVDF membrane. The membrane was probed with 1340 and 1343 antibodies, speci®c for the NH 2 -and COOH-terminal region of BLM, respectively the G2/M phase (6 h). When 95% of the cells were arrested in the G2/M phase (16 h), we observed the appearance of a more rapidly migrating form of the BLM protein. At 24 h of treatment, when all the cells had reached G2/M, the 175 kDa form of BLM had totally disappeared, replaced by the slower and faster migrating bands. At this time point (24 h), more than 95% of cells were actually blocked in metaphase as determined by microscopic inspection of DAPI-stained cells (data not shown). The appearance of the most rapidly migrating form paralleled the strong increase in the slower migrating band, suggesting that it could correspond to a partial degradation of the slow migrating species.
Altogether these results indicate that post-translational modi®cations of BLM occur during mitosis. However, these post-translational modi®cations were not detected in cycling cells sorted at the G2/M phase. To address this apparent paradox, we determined the proportion of mitotic cells in this sorted population. We found that only a few per cent of the cells were in metaphase, as revealed by microscopic inspection of Hoescht-stained cells (data not shown), which may explain why modi®ed forms of BLM were not detected in sorted cells.
To further investigate the relationship between the appearance of the slow migrating band and passage through mitosis, we compared BLM in demecolcineblocked cells versus untreated cells that were enriched for mitotic cells by harvesting from the culture dishes by mechanical shake-o. In cells harvested by mechanical shake-o we found that 25% of cells were in metaphase, versus only 5% in exponentially growing cells, as revealed by DAPI staining (data not shown). As shown in Figure 3c , the slow migrating band was present in cells harvested by mechanical means, but not in exponentially growing cells. These results show that posttranslational modi®cations of BLM occur during mitosis in normally cycling cells, con®rming that the appearance of the slow migrating band in mitotically blocked cells does not result from an artefactual activation of a mitotic phase checkpoint by the drugs demecolcine or taxol.
Post-translational modifications of the BLM protein in mitotic cells correspond to phosphorylations
To determine whether the increase in apparent molecular weight exhibited by the mitotic BLM protein could be assigned to M phase speci®c phosphorylation, BLM protein was immunoprecipitated, using 1340 antibodies, from protein extracts prepared from either unsynchronized or demecolcinearrested HeLa cells. BLM immunoprecipitates were treated with l protein phosphatase, an enzyme which removes phosphate groups appended to amino acids serine, threonine or tyrosine (Zhuo et al., 1993) . As shown in Figure 4 , when l phosphatase was added to BLM immunoprecipitates from unsynchronized cells, the migration of BLM was not aected. However, l phosphatase treatment of BLM immunoprecipitated from mitotic cells resulted in the recovery of a band migrating similar to BLM in unsynchronized cells. These data indicate that the BLM upshift observed in mitotic cells was due to phosphorylation.
Mitotic BLM protein is found in the nucleoplasm but not in the nuclear matrix In order to determine whether the hyperphosphorylated form of BLM associates with a speci®c subcellular compartment in mitosis, we performed subcellular fractionation experiment and analysed the presence of BLM in cytosolic, nucleoplasmic, soluble chromatin and nuclear matrix fractions prepared from unsynchronized or demecolcine-arrested HeLa cells. As shown in Figure 5 , in exponentially growing cells, BLM was observed in the nucleoplasmic and nuclear matrix fractions, in agreement with the results recently published by Gharibyan and Youssou®an (1999) . However, in mitotic cells, the slow migrating form of BLM was totally extracted within the nucleoplasm, and thus not found associated with the nuclear matrix. In contrast, a signi®cant fraction of the moiety remained associated with the nuclear matrix, probably due to the presence, in demecolcine-treated population, of about 10% of cycling cells.
BLM protein is not degraded through the 26S proteasome pathway
Our results that BLM is hyperphosphorylated in mitosis and strongly decreased in G1 phase, suggested that it could be degraded late in mitosis or in early G1. KuÈ hne and Banks (1998) described a short sequence in the amino terminal portion of BLM, SDASLLG, that ®ts the consensus sequence of the L2G box, S/TXXXLLG. This sequence has been associated with ubiquitin-mediated degradation by E6-AP, a thiol acceptor for ubiquitin from the ubiquitin-conjugating E2 enzyme which also displays an intrinsic ubiquitin ligase activity (KuÈ hne and Banks, 1998). To determine whether BLM could be speci®cally targeted for ubiquitin-dependent degradation by the proteasome, HeLa cells were treated for 4 or 24 h with proteasome inhibitors. Proteasome inhibitors treatment results in the accumulation of Figure 4 Treatment of BLM immunoprecipitates with l phosphatase. Proteins extracted from exponentially growing and from demecolcine-treated HeLa cells (0.26 mM for 16 h) were immunoprecipitated using 1340 antibody. BLM immunoprecipitated from asynchronous HeLa cells (lanes 1 and 3) or from demecolcinearrested HeLa cells (lanes 2 and 4) was incubated in the absence (lanes 1 and 2) or the presence (lanes 3 and 4) of 1200 U of l phosphatase at 308C for 2 h. Controls (lanes 1 and 2) were incubated with equivalent amounts of l phosphatase buer without enzyme. All these extracts were separated on 5.5% polyacrylamide gel. Blot membrane was probed with 1340 antibody Figure 5 Subcellular localization of BLM in exponentially growing cells and in metaphase-arrested cells. Cytosolic (lanes 1 and 2), nucleoplasmic (lanes 3 and 4), chromatin associated (lanes 5 and 6) extracts and nuclear matrix fractions (lanes 7 and 8) were prepared from exponentially growing (lanes 1, 3, 5 and 7) and metaphase-arrested (lanes 2, 4, 6 and 8) HeLa cells respectively. Twenty mg of each fraction were separated on 5.5% polyacrylamide gel. Blot membrane was probed with 1340 antibody ubiquitinated forms of proteins thus targeted for degradation by the proteasome, such as b-catenin (Orford et al., 1997; Aberle et al., 1997) . HeLa cells were treated with the speci®c proteasome inhibitor lactacystin (Fenteany et al., 1995) , and with the peptide aldehyde N-acetyl-Leu-Leu-norleucinal or calpain inhibitor I (ALLN), which is known to inhibit proteasome-mediated proteolysis, but also non-proteosomal thiol proteases such as calpains and cathepsins (Coux et al., 1996) . As controls, we also treated cells with N-acetyl-Leu-Leu-methional or calpain inhibitor II (ALLM), a structurally related peptide aldehyde and a potent inhibitor of calpains and cathepsins that does not inhibit the proteolytic activity of the proteasome (Rock et al., 1994) . As shown in Figure  6 , none of these inhibitors resulted in a modi®cation of the expression of BLM, whereas probing the same membrane with an antibody speci®c for b-catenin clearly showed the expected accumulation of high molecular weight species, as previously described (Orford et al., 1997; Aberle et al., 1997) . Identical results were obtained after 24 h treatments (data not shown) or using 1343 antibody directed toward COOH-terminal region of BLM (data not shown). We also carried out the same experiments in cells that have been blocked at mitosis followed by block-release in the presence of proteasome inhibitors. Again, we did not observe any BLM accumulation in the presence of proteasome inhibitors (data not shown). Finally, further attempts to detect ubiquitinated BLM was performed by transfecting transiently HeLa cells with a HA-ubiquitin construction and using the anti-BLM 1343 antibodies to immunoprecipitate BLM from HA-ubiquitin transformed cells, treated or not with demecolcine, with or without proteasome inhibitors. Immunoprecipitates were analysed by Western blot using anti-HA and 1343 antibodies, showing the absence of any retarded or HA-ubiquitintargeted forms of BLM (data not shown). Together, these results strongly suggest that BLM is not a target for the ubiquitin-proteasome pathway.
Discussion
Bloom's syndrome constitutes a genetic and clinical model for recessive cancer predisposition whose study may help in the deciphering of new pathways of carcinogenesis in the general population (German, 1997) . Cells derived from BS patients exhibit a complex phenotype associating in particular replication abnormalities (Hand and German, 1975; Gianneli et al., 1977; Lonn et al., 1990) , high rate of mutations and recombination, and chromosomal breaks (for review, German, 1993) . Even though the BLM gene and several mutations responsible for Bloom's syndrome have been identi®ed in the last 4 years, the physiological function of the gene product remains uncharacterized. In contrast, functional data for the BLM homologs Rqh1 in ®ssion yeast and Sgs1p in budding yeast, have become available that suggest a crucial role for these proteins during the cell cycle (Stewart et al., 1997; Murray et al., 1997; Frei and Gasser, 2000) . These data have prompted us to investigate a regulation of BLM during the cell cycle.
In this study, we have shown that the BLM protein accumulates to high levels during the S phase. This indicates that BLM is likely to act during the S phase, possibly at the level of DNA replication, as already suggested by the observation that BS cells exhibit replication abnormalities, which include a retarded replication-fork elongation (Hand and German, 1975; Gianneli et al., 1977) and abnormal replication intermediates (Lonn et al., 1990) . It is also interesting that BLM carries the L2G box consensus which has been detected in a number of proteins involved in regulation of DNA replication, initiation and/or progression (KuÈ hne and Banks, 1998). Also noteworthy in this respect is the recent report that BLM colocalizes with replication protein A in murine spermatocytes (Walpita et al., 1999) .
Our results showing that high BLM expression levels persist during the G2 phase of the cell cycle, suggest a possible role of BLM also during this phase. BS cells exhibit an increase in interchange between homologous chromosomes at homologous sites, as visualized by an increased number of quadriradial ®gures during metaphase (German, 1993) ; these chromosomal rearrangements are believed to take place during the G2 phase of the cell cycle, suggesting that a normal function of BLM could be to repress somatic recombination. Indeed, loss of heterozygosity as observed in BS cells, an early step in cancer development (for review, Muller and Scott, 1992) , has been previously proposed to be the result of such an increase in somatic recombination (German, 1993) .
The ®nding that BLM is hyperphosphorylated in mitosis, resulting in a high increase of its apparent molecular mass, and that its expression strongly decreases in G1 cells, led us to hypothesize that BLM could be degraded at the time of exit from mitosis through the ubiquitin-proteasome pathway. Several arguments appeared to favor this hypothesis. BLM contains an L2G box (amino-acids 406 ± 432) which could serve as an E6-AP speci®c substrate recognition site for ubiquitination, as described for the Mcm7 protein (KuÈ hne and Banks, 1998). Furthermore, uctuations of BLM levels during the cell cycle were evocative of a protein degraded through the ubiquitin- proteasome pathway, similar to geminin, an inhibitor of DNA replication (McGarry and Kirschner, 1998) , and several cases of phosphorylation promoting ubiquitination have been described (i.e., see Clurman et al., 1996; Lanker et al., 1996) . We thus asked the question whether BLM could be targeted for degradation through a ubiquitin conjugation process. Surprisingly, no polyubiquitinated forms of BLM could be observed, even though the expected accumulation of high molecular weight b-catenin species was already obtained. In light of its striking decrease in expression level in the G1 phase, BLM thus appears to be degraded through a ubiquitin-proteasome independent pathway. In retrospect, this may not be so surprising since the consensus L2G domain observed in the sequence of the human protein is not conserved in the mouse ortholog, suggesting that its presence in human BLM may have no functional relevance. An alternative explanation for the rapid decrease of BLM after mitosis could be that the BLM protein half-life is suciently short that its low G1 expression could merely result from a sharp decrease in protein synthesis at this time of the cell cycle. Future experiments will help to address this question.
Overall, the present data suggest that BLM could act during both the S and G2 phases of the cell cycle. The major cellular consequence of a BLM defect is an increase in homologous recombination (SCE and homologous chromatid interchanges) and in the rate of widespread mutations (German, 1993) . It has been recently con®rmed that homologous recombination is the mechanism responsible for SCE, indicating that DNA lesions accompanying replication can be repaired by homologous recombination using the nascent sister chromatid as template (Sonoda et al., 1999) . Thus, when an unrepaired lesion blocks replication fork progression, two alternative mechanisms can take place: the lesion can be by-passed by translesion synthesis or repaired by homologous recombination through sister chromatid exchanges. These two alternative mechanisms would result in a mutator and a hyper-recombination phenotype, respectively, both characteristic of BS cells. Therefore, the function of BLM is likely to reside in a repair pathway that has not been characterized as yet, but which is predicted to limit the rate of repair through translesion synthesis and homologous recombination. As recently proposed by Chakraverty and Hickson (1999) , our data are consistent with BLM being involved in a`replication fork repair' whose detailed identi®cation will require further studies.
Materials and methods

Chemicals
Demecolcine and Taxol (Sigma) were resuspended in DMSO to a stock concentration of 0.26 mM and 10 mM respectively, and used at the respective dilutions 1 : 1000 and 1 : 10 000. Aphidicolin and Hydroxyurea (Sigma) were resuspended in DMSO and water, respectively, to a stock concentration of 1 mg/ml and 1 M respectively, and used at the respective dilutions 1 : 2000 and 1 : 1000.
The calpain inhibitors N-acetyl-leucyl-leucyl-norleucinal (ALLN) and N-acetyl-leucyl-leucyl-methional (ALLM) (Bachem) were resuspended in anhydrous dimethyl sulfoxide (DMSO) to a stock concentration of 25 mM, and used at 1 : 1000 dilution. Lactacystin (Biomol) was resuspended in anhydrous DMSO to a stock concentration of 2.5 mM and used at 1 : 250 dilution.
In experiments for which these reagents were used, a control including the DMSO alone was added to ensure the absence solvent-generated artifact. No eect of DMSO was found in any of the assays.
Antibodies
The rabbit antiserum 1340 was generated against the aminoterminal peptide of human BLM NH2-NLQEQLERH-SARTLNNKLSLSK-COOH (amino acids 8 ± 29) and the rabbit antiserum 1343 was generated against the carboxyterminal peptide of human BLM NH2-LGIMAPPK-PINRPFLKPSYAFS-COOH (amino acids 1396 ± 1417). These antibodies were used at dilution 1 : 5000. Monoclonal antibody speci®c for the COOH-terminal epitope of mouse b-catenin (Transduction Laboratories) was used at dilution 1 : 2000.
Cell lines
The SV40-transformed ®broblast cell line GM08505B and the EBV-transformed lymphoblastoid B cell line GM03403D, respectively derived from the BS patient 42 (RaFr) and the BS patient 9 (EmSh) of the Bloom's syndrome registry, were obtained from the NIGMS Human Genetic Mutant Cell Repository (Camden, NJ, USA). The HeLa cell line was obtained from the American Tissue Culture Collection and the EBV-transformed lymphoblastoid cell line Priess, derived from a normal individual, was kindly provided by Dr JoeÈ lle Wiels (Institut Gustave Roussy, Villejuif, Paris).
GM08505B and HeLa cells were cultured in Dulbecco's modi®ed Eagle's medium containing 10% heat-inactivated fetal calf serum (FCS). The EBV-transformed lymphoblastoid B cell lines Priess and GM03403D, were cultured in RPMI 1640 medium containing 10% FCS.
To obtain physiological mitotic cells, HeLa cells were divided every day for 3 days. Mitotic cells were then detached from the surface of the culture¯ask by vigorously shaking the¯ask horizontally, several times. The mitotic index of the collected cells was scored by counting 300 cells stained with DAPI under¯uorescence microscope.
Cell cycle analysis
Cells were washed in PBS, suspended in 70% ethanol and stored at 7208C for at least 30 min. Then cells were washed twice in PBS and incubated for 30 min at 378C in PBS containing 100 mg/ml RNase A (Sigma) and 10 mg/ml propidium iodide (Sigma). The DNA content was determined by measuring¯uorescence intensities on a FACScalibur (Becton Dickinson) instrument.
Cell sorting
HeLa cells (30610 6 ) were incubated for 1 h in culture medium containing 10 mg/ml Hoescht 33 342 (Sigma). After washing in PBS, HeLa cells were sorted at G1, S and G2/M phases, according to their DNA content using a FACS Vantage cytometer (Becton Dickinson). A morphologic gate was determined on two-parameters histograms (side scatter versus forward scatter). Part of sorted cells were used to con®rm their quality by¯ow cytometric reanalysis, whereas 3610 5 HeLa cells from each channel were used for BLM expression analysis by Western blotting. Mitotic index of G2/ M sorted cells was scored by counting 300 cells stained with Hoescht 33 342 under¯uorescence microscope.
Western-blot analysis
Cells were cultured with or without drugs, scrapped and lysed in 1% SDS in water for 5 min at 958C and sonicated.
Samples equivalent to 5610 5 cells were subjected to SDSpolyacrylamide (5.5%) gel electrophoresis. Proteins in the gel were electrophoretically transferred to PVDF membranes (Immobilon P, Millipore) in 25 mM Tris-HCl, pH 8.3, 192 mM glycine, 20% methanol for 2 h at 0.8 A. After 1 h saturation in PBS containing 5% dry non-fat milk and 0.5% Tween 20, membrane was incubated for 1 h with primary antibody diluted in PBS containing 5% dry non-fat milk and 0.5% Tween 20. After three washes of 15 min with PBS containing 0.5% Tween 20, membrane was incubated with a 1 : 10 000 dilution of a goat anti-rabbit immunoglobulin G antiserum conjugated to peroxydase (Pierce) or with a 1 : 2000 dilution of a goat anti-mouse immunoglobulin G antiserum conjugated to peroxydase (Zymed). Then membrane was washed three times with PBS containing 0.5% Tween 20, and reaction was developed according to the manufacturer's speci®cations (ECL kit; Amersham). Membrane stripping was performed in 62.5 mM Tris-HCl pH 6.2 with 2% sodium dodecyl sulfate (SDS) and 100 mM b-mercaptoethanol for 30 min at 508C.
Phosphatase treatment
Cells were lysed by incubation in 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM MgCl 2 , 1 mM EDTA, 0.5% Igepal Ca-630 (Sigma), and cocktail of protease inhibitors (Roche), for 15 min at 48C. Membranes debris were eliminated by centrifugation at 14 000 r.p.m. for 15 min. Protein concentration was measured by Coomassie protein assay according to the manufacturer's instructions (Pierce). Immunoprecipitations were performed using 750 mg of lysate for each point. Protein extracts were incubated with 1340 antibody for 16 h at 48C; then, 20 ml of protein A/G-Agarose beads (Santa Cruz) were added and incubation proceeded for another hour. Beads were recovered by low speed centrifugation, washed ®ve times in 0.7 ml of ice-cold wash buer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.25% Igepal Ca-630 and cocktail of protease inhibitors), resuspended in phosphatase buer and then incubated for 2 h at 308C with 1200 U of lambda protein phosphatase in the presence of MnCl 2 , according to the manufacturer's instructions (Biolabs). Controls were incubated with an equivalent amount of buer without phosphatase. Dephosphorylation was stopped by adding an equal volume of Laemmli buer.
Subcellular fractionation
Cells (10610 6 ) were washed in PBS and then snap frozen at 7708C. Cell membranes were lysed by thawing into low salt extraction buer (10 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 0.1 mM EGTA, 0.5 mM DTT, 5% glycerol and cocktail of protease inhibitors) and the nuclei were pelleted by centrifugation at 2200 r.p.m. for 10 min. The supernatant was designated cytosolic fraction. The nuclei were then washed once in low salt extraction buer, resuspended in the same buer adjusted to 0.35 M NaCl, and the mixture was incubated on ice for 1 h to extract nuclear proteins. The insoluble fraction was pelleted by centrifugation at 14 000 r.p.m. for 25 min (the resulting supernatant was designated nucleoplasmic fraction), resuspended in 1 ml of buer A (20 mM Tris-HCl pH 7.4, 5 mM MgCl 2 , 250 mM Sucrose) and incubated for 30 min at 308C with 300 U of Rnase free Dnase I (Roche). The supernatant, after centrifugation for 15 min at 2200 r.p.m., was designated chromatin associated fraction. The pellet was extracted twice with 1 ml of buer B (10 mM Tris-HCl pH 7.4, 0.2 mM MgCl 2 , 2 M NaCl) and spun at 2200 r.p.m. for 15 min. The remaining pellet was solubilized in buer A and considered as the nuclear matrix containing fraction.
Abbreviations BS, Bloom's syndrome; DSB, double-strand break; SCE, sister chromatid exchanges
